Hypertension with coronary heart disease
Conditions
Interventions
Treatment group:Oral midapril hydrochloride
Sponsors
The First Affiliated Hospital of University of South China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) The subjects voluntarily agree to participate in the study and sign a written informed consent; (2) Age 18-75 years old, male or female; (3) In line with the Guidelines for the Diagnosis and Treatment of Coronary Heart Disease and the Chinese Guidelines for the Prevention and Control of Hypertension about CHD and hypertension related diagnostic criteria, and systolic blood pressure >=140mmHg, diastolic blood pressure >=90mmHg
Exclusion criteria
Exclusion criteria: (1) Patients with a history of allergy to the investigational drug or excipient (2) Mental illness, cognitive impairment, unable to communicate normally; (3) have previously taken ACEI or ARB drugs; (4) Active liver disease or liver dysfunction, including unexplained elevation of liver transaminase. Abnormal liver function at baseline (ALT or AST > 3xULN); (5) Known renal insufficiency or elevated serum creatinine level (accompanied by glomerular filtration rate eGFR<=60ml/min/1.73m2); (6) Complicated with malignant tumor, severe valvular heart disease and malignant arrhythmia; (7) Patients with pleural effusion and pneumothorax; (8) The researcher thinks that it is not suitable to participate in this researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antihypertensive efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac function; | — |
Countries
China
Contacts
Public ContactHu Hengjing
The First Affiliated Hospital of University of South China
Outcome results
None listed